

phone 202.955.3500 **fax** 202.955.3599 www.ncqa.org

October 2, 2023

This HEDIS^{®1} Measurement Year (MY) 2023 Public Reporting memo outlines all measures, product lines and indicators approved for public reporting starting in MY 2023 and MY 2024, in addition to all measures, stratifications and product lines that will not be publicly reported for MY 2023.

If you have questions about the information included in the tables, contact us through My NCQA.

Measurement Year	HEDIS Measures/Stratifications That Will Be Publicly Reported
2023	The following first-year and first-year status measures, product lines and indicators will be publicly reported for MY 2023: • Advance Care Planning (ACP). • Antibiotic Utilization for Respiratory Conditions (AXR). • Use of Imaging Studies for Low Back Pain (LBP)—Medicare. • Colorectal Cancer Screening (COL)—Medicaid.
2023	The following measures reported using Electronic Clinical Data Systems (ECDS) will be publicly reported for MY 2023 for all product lines and indicators: • Depression Screening and Follow-Up for Adolescents and Adults (DSF-E). • Utilization of the PHQ-9 to Monitor Depression Symptoms for Adolescents and Adults (DMS-E). • Depression Remission or Response for Adolescents and Adults (DRR-E). • Unhealthy Alcohol Use Screening and Follow-Up (ASF-E). • Follow-Up Care for Children Prescribed ADHD Medication (ADD-E). • Metabolic Monitoring for Children and Adolescents on Antipsychotics (APM-E).
2023	The race and ethnicity stratifications will be publicly reported as aggregate benchmarks (not plan-level results) for MY 2023 for the following measures: • Colorectal Cancer Screening (COL). • Controlling High Blood Pressure (CBP). • Hemoglobin A1c Control for Patients With Diabetes (HBD). • Prenatal and Postpartum Care (PPC). • Child and Adolescent Well-Care Visits (WCV). Benchmarks will capture performance distributions for the race and ethnicity strata in each measure, with plan-level performance aggregated by product line and (potentially) other characteristics such as geographic region.
2024	The following measure using ECDS reporting will be publicly reported for MY 2024 for all product lines and indicators: • Colorectal Cancer Screening (COL-E).

¹HEDIS[®] is a registered trademark of the National Committee for Quality Assurance (NCQA).



Measurement Year	HEDIS Measures/Stratifications That Will Not Be Publicly Reported
2023	The following first-year measures will not be publicly reported for MY 2023: Topical Fluoride for Children (TFC). Oral Evaluation, Dental Services (OED). Deprescribing of Benzodiazepines in Older Adults (DBO). Emergency Department Visits for Hypoglycemia in Older Adults with Diabetes (EDH). Cervical Cancer Screening (CCS-E). Social Need Screening and Intervention (SNS-E).
2023	The race and ethnicity stratifications will not be publicly reported for MY 2023 for the following measures: Immunizations for Adolescents (IMA and IMA-E). Asthma Medication Ratio (AMR). Follow-Up After Emergency Department Visit for Substance Use (FUA). Pharmacotherapy for Opioid Use Disorder (POD). Initiation and Engagement of Substance Use Disorder Treatment (IET). Well-Child Visits in the First 30 Months of Life (W30). Breast Cancer Screening (BCS-E). Colorectal Cancer Screening (COL-E).
2023	The Medicare Socioeconomic Status Stratifications (SES) for the following measures will not be publicly reported for MY 2023: • Colorectal Cancer Screening (COL and COL-E). • Eye Exam for Patients With Diabetes (EED). • Plan All-Cause Readmissions (PCR). • Breast Cancer Screening (BCS-E).
2023	The following measures reported using ECDS will not be publicly reported for MY 2023: • Colorectal Cancer Screening (COL-E). • Childhood Immunization Status (CIS-E). • Immunizations for Adolescents (IMA-E).